The study you're referring to was done by two of the leading economists in the pharmaceutical sector in Canada: Aidan Hollis at the University of Calgary and Paul Grootendorst at the University of Toronto. It's their numbers.
They simply looked at the recent launches of generic products and asked what would have happened had those products been delayed according to the proposals. Barry mentioned one example, Lipitor. What would have happened to those? That's when they determined that, on average, new generic products would be delayed three and a half years. They then looked at the different pricing of generics—25% to 35% of the equivalent brand—and compared what the extra costs would be.
It's all laid out in their study—how they did the analysis—and the costs are there. If people want to change the assumptions or do different assumptions, they're all laid out. We have not seen any other analysis that challenges—